Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: Phase IIIb LUCY final analysis
Balmana J, Fasching P, Delaloge S, Park YH, Eisen A, Bourgeois H, Kemp Z, Jankowski T, Sohn J, Aksoy S, Timcheva CV, Park-Simon TW, Torres AA, John E, Baria K, Walker G, Gelmon KA (2022)
Publication Type: Conference contribution
Publication year: 2022
Journal
Publisher: ELSEVIER
City/Town: AMSTERDAM
Pages Range: S205-S206
Conference Proceedings Title: ANNALS OF ONCOLOGY
DOI: 10.1016/j.annonc.2022.03.193
Authors with CRIS profile
Involved external institutions
Vall d'Hebron University Hospital / Hospital Universitari Vall d'Hebron
Spain (ES)
Institut Gustave-Roussy
France (FR)
Sungkyunkwan University (SKKU)
Korea, Republic of (KR)
Sunnybrook Health Sciences Centre
Canada (CA)
Centre Jean Bernard: Institut Inter-régional de Cancérologie
France (FR)
National Health Service (NHS)
United Kingdom (GB)
Lublin Oncology Center / Centrum Onkologii Ziemi Lubelskiej (COZL)
Poland (PL)
Yonsei University
Korea, Republic of (KR)
Nadezhda Hospital
Bulgaria (BG)
Hacettepe University
Turkey (TR)
Medizinische Hochschule Hannover (MHH) / Hannover Medical School
Germany (DE)
Hospital Universitario Miguel Servet
Spain (ES)
AstraZeneca UK Limited
United Kingdom (GB)
University of British Columbia
Canada (CA)
Spain (ES)
Institut Gustave-Roussy
France (FR)
Sungkyunkwan University (SKKU)
Korea, Republic of (KR)
Sunnybrook Health Sciences Centre
Canada (CA)
Centre Jean Bernard: Institut Inter-régional de Cancérologie
France (FR)
National Health Service (NHS)
United Kingdom (GB)
Lublin Oncology Center / Centrum Onkologii Ziemi Lubelskiej (COZL)
Poland (PL)
Yonsei University
Korea, Republic of (KR)
Nadezhda Hospital
Bulgaria (BG)
Hacettepe University
Turkey (TR)
Medizinische Hochschule Hannover (MHH) / Hannover Medical School
Germany (DE)
Hospital Universitario Miguel Servet
Spain (ES)
AstraZeneca UK Limited
United Kingdom (GB)
University of British Columbia
Canada (CA)
How to cite
APA:
Balmana, J., Fasching, P., Delaloge, S., Park, Y.H., Eisen, A., Bourgeois, H.,... Gelmon, K.A. (2022). Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: Phase IIIb LUCY final analysis. In ANNALS OF ONCOLOGY (pp. S205-S206). AMSTERDAM: ELSEVIER.
MLA:
Balmana, J., et al. "Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: Phase IIIb LUCY final analysis." Proceedings of the ANNALS OF ONCOLOGY AMSTERDAM: ELSEVIER, 2022. S205-S206.
BibTeX: Download